Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance

Abstract Poly‐ADP‐ribose polymerase (PARP) inhibitors (PARPi) have shown great promise for treating BRCA‐deficient tumors. However, over 40% of BRCA‐deficient patients fail to respond to PARPi. Here, we report that thioparib, a next‐generation PARPi with high affinity against multiple PARPs, includi...

Full description

Saved in:
Bibliographic Details
Main Authors: Li‐Min Wang, Pingyuan Wang, Xiao‐Min Chen, Hui Yang, Shan‐Shan Song, Zilan Song, Li Jia, Hua‐Dong Chen, Xu‐Bin Bao, Ne Guo, Xia‐Juan Huan, Yong Xi, Yan‐Yan Shen, Xin‐Ying Yang, Yi Su, Yi‐Ming Sun, Ying‐Lei Gao, Yi Chen, Jian Ding, Jing‐Yu Lang, Ze‐Hong Miao, Ao Zhang, Jin‐Xue He
Format: Article
Language:English
Published: Springer Nature 2023-01-01
Series:EMBO Molecular Medicine
Subjects:
homologous recombination repair
olaparib‐resistant
PARP inhibitor
PARP7
type I interferons
Online Access:https://doi.org/10.15252/emmm.202216235
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.202216235

Similar Items